| Terry R Routt, LCSW | |
|
570 E 1400 S, Orem, UT 84097-7714 | |
| (801) 426-6661 | |
| (801) 426-6660 |
| Full Name | Terry R Routt |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 570 E 1400 S, Orem, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023212644 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 134709-3501 (Utah) | Primary |
| Entity Name | Chrysalis Utah, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891898045 PECOS PAC ID: 4284735846 Enrollment ID: O20070726000156 |
News Archive
An Australian study conducted at the University of Melbourne describes that the emergence of more deadly variants of concern (VOCs) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with an induction in episodic evolutionary rate. The study is currently available on the medRxiv* preprint server.
A team of UK-based scientists has recently evaluated the effectiveness of coronavirus disease 2019 (COVID-19) vaccines in preventing household transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in England.
Despite one in 10 people worldwide having chronic kidney disease, a new global report - The Global Kidney Health Atlas - presented at this week's World Congress of Nephrology in Mexico City and compiled by the International Society of Nephrology and kidney health experts worldwide and published in JAMA- highlights the huge gaps in kidney disease care and prevention in both developed and developing countries, with many countries not prioritising kidney health.
USA Today/Indianapolis Star: Drugmakers are facing an array of challenges, like lawsuits and patent losses, but also new opportunities including global growth and an expected surge in the number of U.S. residents with health insurance. Eli Lilly CEO John Lechleiter comments in a Q&A: "The biggest challenge facing the industry is to be able to sustain the flow of innovative medicines from our pipelines that can effectively compete against the generic versions of our own products" (Chu, 7/21).
ARIAD Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase 2 clinical trial of its investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Terry R Routt, LCSW 756 W 1150 S, Provo, UT 84601-5542 Ph: (801) 371-0968 | Terry R Routt, LCSW 570 E 1400 S, Orem, UT 84097-7714 Ph: (801) 426-6661 |
News Archive
An Australian study conducted at the University of Melbourne describes that the emergence of more deadly variants of concern (VOCs) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with an induction in episodic evolutionary rate. The study is currently available on the medRxiv* preprint server.
A team of UK-based scientists has recently evaluated the effectiveness of coronavirus disease 2019 (COVID-19) vaccines in preventing household transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in England.
Despite one in 10 people worldwide having chronic kidney disease, a new global report - The Global Kidney Health Atlas - presented at this week's World Congress of Nephrology in Mexico City and compiled by the International Society of Nephrology and kidney health experts worldwide and published in JAMA- highlights the huge gaps in kidney disease care and prevention in both developed and developing countries, with many countries not prioritising kidney health.
USA Today/Indianapolis Star: Drugmakers are facing an array of challenges, like lawsuits and patent losses, but also new opportunities including global growth and an expected surge in the number of U.S. residents with health insurance. Eli Lilly CEO John Lechleiter comments in a Q&A: "The biggest challenge facing the industry is to be able to sustain the flow of innovative medicines from our pipelines that can effectively compete against the generic versions of our own products" (Chu, 7/21).
ARIAD Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase 2 clinical trial of its investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).
› Verified 8 days ago
Katie Fishman, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 600 S Geneva Rd, Orem, UT 84059 Phone: 801-877-5300 | |
Alicia Hills, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 202 E 800 S Ste 105, Orem, UT 84058 Phone: 385-283-1032 | |
Morgan Oliphant, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1255 N 1200 W, Orem, UT 84057 Phone: 801-229-1181 | |
Rebecca Jane Mcnairy, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1125 W Center St, Orem, UT 84057 Phone: 801-903-5903 | |
Erin Elizabeth Vasquez, LCSW, RPT Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1255 N 1200 W, Orem, UT 84057 Phone: 801-229-1181 Fax: 801-229-2787 | |
Mr. Mark James Capell, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 313 E 1200 S, Suite 104, Orem, UT 84058 Phone: 801-377-1595 Fax: 801-377-1598 |